Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Bayer Oy

Home Clinical Trial Sponsors and OrganizationsBayer Oy

Bayer Oy

Utländsk Adr - Foreign Addr, Sweden

Also known as:

medikalis

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

2

2 active

Approvals

18

Total approvals

Agencies

4

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

No trial phase data available

Trial Status Distribution

Active, not recruiting

2

100.0%

Clinical Trials

Trials sponsored by this organization (2)

Multi-center, open-label, randomized study to assess the safety and contraceptive efficacy of two doses (in vitro 12 µg/24 h and 16 µg/24 h) of the ultra low dose levonorgestrel contraceptive intrauterine systems (LCS) for a maximum of 3 years in women 18 to 35 years of age and an extension phase of the 16 µg/24h dose group (LCS16 arm) up to 5 years. - LCS Pearl Index Study

Active, not recruiting

Sep 20072,820 participants

A randomized, double-blind, double-dummy, multi-center, parallel group study to compare the tolerability and efficacy of once daily vardenafil versus vardenafil PRN versus placebo in men immediately after nerve-sparing prostatectomy for improving erectile function.REINVENT (Recovery of Erections: INtervention with Vardenafil Early Nightly Therapy) - REINVENT

Active, not recruiting

Nov 2004828 participants

Approvals

Approvals by Agency

NMPA

National Medical Products Administration

9

Approvals

PHILIPPINES

Philippines FDA

2

Approvals

SFDA

Saudi Food and Drug Authority

5

Approvals

NPRA

National Pharmaceutical Regulatory Agency

2

Approvals

Recent Approvals

MIRENA INTRAUTERINE SYSTEM 20MCG/24 HOURS

JADELLE IMPLANTS

RECOFOL 10MG-ML INJECTION

MIRENA 52 MG INTRAUTERINE DELIVERY SYSTEM (IUS)

RECOFOL 20MG-ML I.V. EMULSION FOR INFU

RECOFOL 10MG-ML INJECTION

RECOFOL 10MG-ML INJECTION

Levonorgestrel Intrauterine System(Ⅲ)

News

No news articles found

On this page

Overview
Clinical Trials2
Approvals18
News

Back to Organizations